The occurrence of invasive cancers following a diagnosis of breast carcinoma in situ

British Journal of Cancer

Volumn 99, Issue 4, 2008, Pages 611-615

  Robinson, D ^a   Holmberg, L ^b   Moller H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

Breast carcinoma in situ; Hormonal therapy; Second cancers; Uterine cancer

Indexed keywords

HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER INVASION; CANCER REGISTRY; CANCER RISK; CARCINOMA IN SITU; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONSERVATIVE TREATMENT; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; HAZARD RATIO; HEAD AND NECK CANCER; HORMONAL THERAPY; HUMAN; INCIDENCE; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STOMACH CANCER; THERAPY EFFECT; TIME; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERUS CANCER;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; ENGLAND; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, SECOND PRIMARY; POPULATION SURVEILLANCE; RISK FACTORS;

EID: 49549115730     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604524     Document Type: Article

References (34)

1. Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83: 1013-1017
2. Atlante G, Pozzi M, Vincenzoni C, Vocaturo G (1990) Four case reports presenting new acquisitions on the association between breast and endometrial carcinoma. Gynecol Oncol 37: 378-380
3. Bijker N, Meijnen P, Peterse JL, Bogaerts J, van Hoorebeeck I, Julien J-P, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ (2006) Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: ten-year results of European Organisation for Research and Treatment of Cancer Randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24: 3381-3387
4. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23: 5534-5541
5. Claus EB, Stowe M, Carter D, Holford T (2003) The risk of a contralateral breast cancer among women diagnosed with ductal and lobular breast carcinoma in situ: data from the Connecticut Tumor Registry. Breast 12: 451-456
6. Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson L-G, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A (2006) SweDCIS: radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol 45: 536-543
7. Evans HS, Lewis CM, Robinson D, Bell CMJ, Møller H, Hodgson SV (2001) Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England. Br J Cancer 84: 435-440
8. Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, Wolmark N, Wickerham DL, Deutsch M, Ore L, Mamounas E, Poller W, Kavanah M (1993) Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 328: 1581-1586
9. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537
10. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, Fisher ER, Wickerham DL, Deutsch M, Margolese R, Dimitrov N, Kavanah M (1998) Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16: 441-452
11. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH (1999) Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353: 1993-2000
12. Fornander T, Rutqvist LE, Cedermark B, Glas U, Mattson A, Silfverswärd C, Skoog L, Somell A, Theve T, Wilking N (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1: 117-120
13. Franceschi S, Levi F, La Vecchia C, Randimbison L, Te V-C (1998) Second cancers following in situ carcinoma of the breast. Int J Cancer 77: 392-395
14. Frykberg ER, Santiago F, Betsill Jr WL, O'Brien PH (1987) Lobular carcinoma in situ of the breast. Surg Gynecol Obstet 164: 285-301
15. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V (1999) Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 91: 1829-1846
16. Gusberg SB (1990) Tamoxifen for breast cancer: associated endometrial cancer. Cancer 65: 1463-1464
17. Habel LA, Moe RE, Daling JR, Holte S, Rossing MA, Weiss NS (1997) Risk of contralateral breast cancer among women with carcinoma in situ of the breast. Ann Surg 225: 69-75
18. Hardell L (1988) Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 3: 563
19. Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M (2003) Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet 362: 95-102
20. Jack RH, Davies EA, Robinson D, Sainsbury R, Møller H (2007) Radiotherapy waiting times for women with breast cancer: a population-based study. BMC Cancer 7: 71 (http://www.biomedcentral.com/ 1471-2407/7/71)
21. Julien JP, Bijker N, Fentiman IS, Peterse JL, Delledonne V, Rouanet P, Avril A, Sylvester R, Mignolet F, Bartelink H, van Dongen JA (2000) Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. Lancet 355: 528-533
22. Khandekar JD, Victor TA, Mukhopadhyaya P (1978) Endometrial carcinoma following estrogen therapy for breast cancer. Report of three cases. Arch Intern Med 138: 539-541
23. Levi F, Randimbison L, Te V-C, La Vecchia C (2005) Invasive breast cancer following ductal and lobular carcinoma in situ of the breast. Int J Cancer 116: 820-823
24. Mathew A, Chabon AB, Kabakow B, Drucker M, Hirschman RJ (1990) Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med 90: 207-208
25. NHS Breast Screening Programme (2006) Annual Review 2006. Sheffield: NHS Cancer Screening Programmes
26. Page DL, Kidd Jr TE, Dupont WD, Simpson JF, Rogers LW (1991) Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Hum Pathol 22: 1232-1239
27. Rawal R, Lorenzo Bermejo J, Hemminki K (2005) Risk of subsequent invasive breast carcinoma after in situ breast carcinoma in a population covered by national mammographic screening. Br J Cancer 92: 162-166
28. Ringberg A, Nordgren H, Thorstensson S, Idvall I, Garmo H, Granstrand B, Arnesson LG, Sandelin K, Wallgren A, Anderson H, Emdin S, Holmberg L (2007) Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast-results from the Swedish randomised trial. Eur J Cancer 43: 291-298
29. Robinson D, Massey T, Davies E, Jack RH, Sehgal A, Møller H (2005) Waiting times for radiotherapy: variation over time and between cancer networks in southeast England. Br J Cancer 92: 1201-1208
30. Roychoudhuri R, Evans H, Robinson D, Møller H (2004) Radiation-induced malignancies following radiotherapy for breast cancer. Br J Cancer 91: 868-872
31. Rubino C, de Vathaire F, Shamsaldin A, Labbe M, Lê MG (2003) Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 89: 840-846
32. Soerjomataram I, Louwman WJ, van der Sangen MJC, Roumen RMH, Coebergh JWW (2006) Increased risk of second malignancies after in situ breast carcinoma in a population-based registry. Br J Cancer 95: 393-397
33. Ward BA, McKhann CF, Ravikumar TS (1992) Ten-year follow-up of breast carcinoma in situ in Connecticut. Arch Surg 127: 1392-1395
34. Wärnberg F, Yuen J, Holmberg L (2000) Risk of subsequent invasive breast cancer after breast carcinoma in situ. Lancet 355: 724-725